Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe

Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases,...

Full description

Bibliographic Details

Published in:	Frontiers in Endocrinology
Main Authors:	Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	anti-osteoporotic drugs non-alcoholic fatty liver disease denosumab romosozumab bisphosphonates calcitonin
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1344376/full